PCVX Vaxcyte, Inc.

Vaxcyte, Inc. engages in development of vaccines for infectious diseases. It focuses on conjugate vaccines and protein-based vaccines developed through Sutro Biopharma's Xpress CF Platform, a cell-free protein synthesis technology. The company was founded by Grant E. Pickering, Ashish Khanna and Jeff Fairman on November 27, 2013 and is headquartered in San Francisco, CA.

$22.66  -1.57 (-6.48%)
As of 10/04/2022 12:25:09 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/12/2020
Outstanding shares:  59,315,134
Average volume:  581,308
Market cap:   $1,423,563,216
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BKPVGH6
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   3.81
PS ratio:   0.00
Return on equity:   -32.78%
Net income %:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy